J 2021

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

KOESSLER, T., M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. P. LUTZ et. al.

Basic information

Original name

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Authors

KOESSLER, T. (guarantor), M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. P. LUTZ, Radka OBERMANNOVÁ (203 Czech Republic, belonging to the institution), M. PEETERS, F. SCLAFANI, E. SMYTH, J. W. VALLE, A. D. WAGNER, L. WYRWICZ, E. FONTANA and M. MOEHLER

Edition

British journal of cancer, London, Nature Publishing Group, 2021, 0007-0920

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 9.075

RIV identification code

RIV/00216224:14110/21:00124160

Organization unit

Faculty of Medicine

UT WoS

000687550400002

Keywords in English

Gastrointestinal tract cancer; ASCO-GI 2021

Tags

International impact, Reviewed
Změněno: 15/2/2022 12:33, Mgr. Tereza Miškechová

Abstract

V originále

Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.